Risk of Ovarian Malignancy Algorithm
Also known as: ROMA
Use
The Risk of Ovarian Malignancy Algorithm (ROMA) assesses the likelihood of malignancy in women with an ovarian adnexal mass, taking into account factors like HE4, CA125, and menopausal status. It is particularly useful for evaluating the risk of epithelial ovarian cancer in pre- and postmenopausal women before surgery. However, it is not intended as a sole method for cancer screening or monitoring and should be used alongside clinical and radiological evaluations. A ROMA score below specified thresholds for premenopausal and postmenopausal women suggests a low malignancy risk during surgical intervention.
Special Instructions
ROMA is recommended for women over 18 with an ovarian adnexal mass for whom surgery is planned and who have not yet consulted with an oncologist. The results should be interpreted with independent clinical assessments.
Limitations
ROMA should not be used as a stand-alone test for ovarian cancer screening or for monitoring purposes. It must be supplemented with HE4 and/or CA125 tests for tumor monitoring. Results obtained from different methodologies or kits are not interchangeable, which may affect consistency in diagnosis or interpretation of malignancy risk.
New York Approved
Methodology
Immunoassay (ECLIA)
Biomarkers
LOINC Codes
- 55180-4
- 62364-5
- 69569-2
- 69570-0
- 83082-8
- 69569-2
- 69570-0
- 83082-8
- 55180-4
- 62364-5
Result Turnaround Time
1 day
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1.5 mL
Minimum Volume
1 mL
Container
Serum Separator Tube (SST), Green (Lithium Heparin), Lavender (EDTA), Pink (K2 EDTA)
Collection Instructions
Allow specimen to clot completely at room temperature. Transfer to an ARUP Standard Transport Tube.
Causes for Rejection
Hemolyzed specimens
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 5 hours |
| Refrigerated | 48 hours |
| Frozen | 3 months |
Other tests from different labs that may be relevant